These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 16997053)

  • 1. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].
    Busch M; Franke S; Stein G; Wolf G;
    Dtsch Med Wochenschr; 2007 Sep; 132(36):1810-4. PubMed ID: 17726651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum carboxymethyllysine predicts mortality in hemodialysis patients.
    Wagner Z; Molnár M; Molnár GA; Tamaskó M; Laczy B; Wagner L; Csiky B; Heidland A; Nagy J; Wittmann I
    Am J Kidney Dis; 2006 Feb; 47(2):294-300. PubMed ID: 16431258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
    Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and prognostic value of advanced glycation end-products in chronic heart failure.
    Hartog JW; Voors AA; Schalkwijk CG; Scheijen J; Smilde TD; Damman K; Bakker SJ; Smit AJ; van Veldhuisen DJ
    Eur Heart J; 2007 Dec; 28(23):2879-85. PubMed ID: 17986469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study.
    Kilhovd BK; Juutilainen A; Lehto S; Rönnemaa T; Torjesen PA; Birkeland KI; Berg TJ; Hanssen KF; Laakso M
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):815-20. PubMed ID: 15692098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of advanced glycation end products in children with renal disease.
    Sebeková K; Podracká L; Blazícek P; Syrová D; Heidland A; Schinzel R
    Pediatr Nephrol; 2001 Dec; 16(12):1105-12. PubMed ID: 11793110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy.
    Lo MK; Lee KF; Chan NN; Leung WY; Ko GT; Chan WB; So WY; Ng MC; Ho CS; Tam JS; Lam CW; Tong PC; Chan JC
    Diabetes Obes Metab; 2004 May; 6(3):223-30. PubMed ID: 15056131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes.
    Zoppini G; Targher G; Chonchol M; Perrone F; Lippi G; Muggeo M
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):580-6. PubMed ID: 19196499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.
    Endo M; Yanagisawa K; Tsuchida K; Okamoto T; Matsushita T; Higuchi M; Matsuda A; Takeuchi M; Makita Z; Koike T
    Horm Metab Res; 2001 May; 33(5):317-22. PubMed ID: 11440280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
    Jafar TH; Schmid CH; Stark PC; Toto R; Remuzzi G; Ruggenenti P; Marcantoni C; Becker G; Shahinfar S; De Jong PE; De Zeeuw D; Kamper AL; Strangaard S; Levey AS
    Nephrol Dial Transplant; 2003 Oct; 18(10):2047-53. PubMed ID: 13679479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel advanced glycation index and its association with diabetes and microangiopathy.
    Sampathkumar R; Balasubramanyam M; Rema M; Premanand C; Mohan V
    Metabolism; 2005 Aug; 54(8):1002-7. PubMed ID: 16092048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein.
    Busch M; Franke S; Müller A; Wolf M; Gerth J; Ott U; Niwa T; Stein G
    Kidney Int; 2004 Jul; 66(1):338-47. PubMed ID: 15200442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severity of diabetic microvascular complications is associated with a low soluble RAGE level.
    Grossin N; Wautier MP; Meas T; Guillausseau PJ; Massin P; Wautier JL
    Diabetes Metab; 2008 Sep; 34(4 Pt 1):392-5. PubMed ID: 18701333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant macro and microvascular complications in diabetic nephropathy.
    Alwakeel JS; Al-Suwaida A; Isnani AC; Al-Harbi A; Alam A
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):402-9. PubMed ID: 19414942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy.
    Ogawa Y; Goto T; Tamasawa N; Matsui J; Tando Y; Sugimoto K; Tomotsune K; Kimura M; Yasujima M; Suda T
    Diabetes Res Clin Pract; 2008 Feb; 79(2):357-61. PubMed ID: 17980929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.